Table 4.
Characteristics of patients treated with ICS/LABA fixed combinations for at least 4 weeks before the 12-month follow-up visit
| Total n = 569 | BDP/F extrafine n = 301 | BUD/F n = 145 | FP/S n = 123 | Overall p-value | |
|---|---|---|---|---|---|
| Level of asthma control, n (%) |
|
|
|
|
0.001(1) |
| Fully controlled |
108 (19.0) |
77 (25.6) |
12 (8.3) |
19 (15.4) |
|
| Controlled |
351 (61.7) |
173 (57.5) |
102 (70.3) |
76 (61.8) |
|
| Partly controlled |
68 (12.0) |
31 (10.3) |
18 (12.4) |
19 (15.4) |
|
| Uncontrolled |
42 (7.4) |
20 (6.6) |
13 (9.0) |
9 (7.3) |
|
| Current smokers, n (%) |
110 (19.3) |
69 (22.9) |
25 (17.2) |
16 (13.0) |
0.617 |
| Fully controlled |
25 (22.7) |
20 (29.0) |
3 (12.0) |
2 (12.5) |
0.135 |
| Controlled |
66 (60.0) |
39 (56.5) |
17 (68.0) |
10 (62.5) |
|
| Partly controlled |
12 (10.9) |
7 (10.1) |
3 (12.0) |
2 (12.5) |
|
| Uncontrolled |
7 (6.4) |
3 (4.4) |
2 (8.0) |
2 (12.5) |
|
| ACT score, mean (SD) |
21.5 (3.4) |
22.0 (3.4) |
20.7 (3.6) |
21.3 (3.3) |
<0.001(2) |
| Improvement of 3 points in ACT score, n (%) |
493 (86.6) |
268 (89.0) |
116 (80.0) |
109 (88.6) |
0.024(3) |
| Daily Dose of ICS, n |
537 |
287 |
141 |
122 |
|
| Mean mcg (SD) |
NA |
318.8 (114.3) |
651.1 (291.2) |
750.6 (371.7) |
<0.001(4) |
| Patients with exacerbation, n (%) (5) | 84 (14.8) | 40 (13.3) | 19 (13.1) | 25 (20.3) | 0.145 |
BDP/F: beclomethasone/formoterol; BUD/F: budesonide/formoterol; FP/S: fluticasone/salmeterol; (1) Bonferroni’s corrected p = 0.001 BDP/F vs. BUD/F; (2) Bonferroni’s corrected p < 0.001 BDP/F vs. BUD/F; Bonferroni’s corrected p = 0.039 BDP/F vs. FP/S; (3) Bonferroni’s corrected p = 0.029 BDP/F vs. BUD/F; (4) Bonferroni’s corrected p < 0.001 BDP/F vs. BUD/F and FP/S; Bonferroni’s corrected p < 0.001 BUD/F vs. FP/S; (5) Reported in the last 3 months before the 12-month visit.